ARS Pharmaceuticals (SPRY) Other Non-Current Liabilities (2021 - 2026)

ARS Pharmaceuticals (SPRY) posted Other Non-Current Liabilities of $4.5 million for Q1 2026, down 2.76% sequentially from $4.6 million in Q4 2025.

Analysis

ARS Pharmaceuticals (SPRY) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends

ARS Pharmaceuticals has reported Other Non-Current Liabilities for 3 years, with the latest figure at $4.5 million in Q1 2026.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (changed N/A YoY) and the FY2025 annual result came in at $4.6 million, changed N/A from the prior year.
Other Non-Current Liabilities fell to $4.5 million in Q1 2026 per SPRY's latest filing, from $4.6 million in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $4.6 million in Q4 2025 and troughed at $1.4 million in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	ARS Pharmaceuticals	561.12 Mn	417.27 Mn	20.81 Mn

Historic Data

Download Data